Ligand製藥 LGND 深 滬
等待開盤 09-20 09:30:00 美东时间
105.01
+1.330
+1.28%
華盛通- 最 高106.20
- 今 開105.41
- 成交量 8.62万股
- 最 低 104.35
- 昨 收 103.68
- 總市值 18.59亿
- 52周最高 112.125
- 市盈率 靜 35.75
- 換手率 0.49%
- 52周最低 49.24
- 委 比 32.23%
- 總股本 1770.53万
- 歷史最高 248.6071
- 量 比 1.04
- 振 幅 1.78%
- 歷史最低 -19.8529
- 每 手 1
- 風險率 15.74%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Travere gains on full FDA approval for kidney drug Filspari
Travere Therapeutics (NASDAQ:TVTX) traded higher in the premarket on Friday after the U.S. Food and Drug Administration (FDA) granted full approval for its kidney disease drug, Filspari (sparsentan). ...
09-06 18:45
Looking Into Ligand Pharmaceuticals's Recent Short Interest
Ligand Pharmaceuticals's (NYSE:LGND) short percent of float has fallen 14.7% si...
08-16 21:01
Roth MKM says Small-Cap Value reaches key technical support, lists 14 "bullish" stocks
With so much focus on large-cap (SP500)and growth stocks, Roth MKM highlighted the small-cap (RTY) value pocket of the U.S. equity market and listed some “bullish” stocks in the group. Looking at the...
08-12 23:34
Ligand Pharmaceuticals COO Matthew Korenberg to depart
Ligand Pharmaceuticals (NASDAQ:LGND) announced that its President and Chief Operating Officer, Matthew Korenberg, will be departing from the company. Filing More on Ligand Pharmaceuticals Ligand Phar...
08-03 05:53
Ligand Pharma’s President to Depart, Continues as Consultant
Ligand Pharma (LGND) has provided an announcement. Ligand Pharmaceuticals has a...
08-03 05:51
Assessing Ligand Pharmaceuticals: Insights From 6 Financial Analysts
In the preceding three months, 6 analysts have released ratings for Ligand Phar...
07-30 20:01
Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement
Proposed merger to create a Nasdaq-listed, clinical-stage biopharmaceutical com...
07-24 18:30
Amgen, Garmin among relative market leaders poised to outperform in coming months: BTIG
BTIG screened for relative leadership during the market’s recent pullback and identified 12 stocks it expects to fare well over the coming months, including private equity firm Blackstone (NYSE:BX), b...
07-23 22:38
J&J beats in Q2 as pharma segment outperforms
Johnson & Johnson (NYSE:JNJ) posted better-than-expected financials for Q2 2024 on Wednesday, thanks mainly to its pharma unit, currently known as Innovative Medicine, while its MedTech division fell ...
07-17 19:16
Ligand to buy APEIRON Biologics for $100M, ups 2024 revenue outlook
Ligand Pharmaceuticals (NASDAQ:LGND) said it will acquire APEIRON Biologics for $100 million in cash. Additionally, the company will pay APEIRON shareholders additional consideration based on future c...
07-08 19:17
